Health Care Technology
Company Overview of Molecular Health AG
Molecular Health AG, a clinico-molecular informatics company, develops precision medicine by translating patient-specific molecular and genomic data, clinical history, and published scientific and medical evidence into drug choices for patients. The company offers clinico-molecular informatics solutions ranging from a drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support system that transforms genome sequences into evidence-based treatment strategies for cancer patients. Its solutions analyze and synthesize extensive bodies of molecular, biomedical, and clinical evidence; map results to a patient’s clinico-molecular sta...
Founded in 2004
Key Executives for Molecular Health AG
Senior Vice President of Finance
Chief Operating Officer and Executive Vice President
Compensation as of Fiscal Year 2014.
Molecular Health AG Key Developments
MolecularHealth Appoints Gabriel Bien-Willner as Medical Director for U.S. Next-Generation Sequencing Lab
Jul 14 14
MolecularHealth announced the appointment of Gabriel Bien-Willner as medical director of its CLIA-certified next-generation sequencing lab in The Woodlands, Texas. Dr. Bien-Willner will report to Chief Medical Officer Dr. Shelly Gunn and manage the day-to-day clinical duties of the laboratory. Dr. Bien-Willner has expertise in genetics and genomics, next-generation sequencing technology and pipeline design.
MolecularHealth Launches MolecularHealth COPE
Jun 5 14
MolecularHealth announced the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP. COPE enables self-funded employers to offer access to TreatmentMAP to their employees via a pre-packaged offering, which includes materials for employees, as well as working closely with patients' physicians through the process of testing, analyzing and receiving results. SAP is working with MolecularHealth to become one of the first organizations to provide its employees with access to COPE and plans to offer it in the third quarter of 2014. SAP technology also plays a role in enabling COPE; the SAP Genomic Analyzer solution running on the SAP HANA platform is used in an early adoption phase to speed up the genome alignment process by a factor of 300 compared to previously used algorithms. TreatmentMAP generates an individual tumor analysis for each patient and then provides a clinical interpretation of the genomic patient data to support the patient's physician in making an individualized treatment decision. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic testing. Now, for the first time and in a clear and understandable way, physicians and individuals diagnosed with cancer will have access to actionable information to guide the selection of cancer treatments. The TreatmentMAP offering, available from MolecularHealth offices in the United States and in Europe, is accessible to all patients diagnosed with solid tumor cancer, regardless of where they live.
MolecularHealth Announces the Appointment of Waun Ki Hong to Advisory Board
May 29 14
MolecularHealth announced Waun Ki Hong, M.D., as the newest member of its advisory board. Dr. Hong is one of the nation’s experts on head, neck and lung cancers. Currently, Dr. Hong serves as the head of the cancer medicine division at the University of Texas MD Anderson Cancer Center. He is also an American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, professor of thoracic/head and neck medical oncology, and former president of the American Association for Cancer Research.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|